Loading...

SNDX SYNDAX PHARMACEUTICALS INC Management Changes 8-K Filing

SYND

SNDX

SYNDAX PHARMACEUTICALS INC

(SNDX)

2025 8-K

Financial Results Announcement

Financial Update

Bylaw Amendments

Financial Results

FDA Approval Announcement

Financial Statements

Financial Statements

Financial Results

Positive Trial Results

Financial Results

Royalty Sale Agreement

Financial Results Announcement

Appointment and Resignation

Financial Results Announcement

Appointment of Chief Commer...

Financial Results Announcement

Public Offering

Agreement for Stock Issuance

Updates on Clinical Programs

Financial Results Announcement

Financial Results Announcement

Product Updates

Termination of Sales Agreem...

Amendment to Certificate of...

Financial Results Announcement

Appointment and Resignation

Financial Results Announcement

Approval of 2023 Inducement...

External Links:

On May 12, 2025, Syndax Pharmaceuticals appointed Nicholas A.J. Botwood as Chief Medical Officer and Head of Research, replacing Neil Gallagher who resigned; Botwood's salary is $540,000 with a bonus target of 45% and stock options for 215,000 shares.

AI Assistant

SYNDAX PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.